Why the study?
Does the plasma copeptin level at initial presentation help differentiate Tako-Tsubo cardiomyopathy from acute myocardial infarction?
Does the plasma copeptin level at initial presentation help differentiate Tako-Tsubo cardiomyopathy from acute myocardial infarction?
Plasma copeptin levels are significantly lower in Tako-Tsubo cardiomyopathy compared to acute myocardial infarction, suggesting its potential utility as a non-invasive biomarker for differentiating the two conditions.
May support copeptin to differentiate TTC from AMI at presentation; leaves open prospective validation before clinical adoption.
BACKGROUND: As the clinical, electrocardiographic and laboratory presentation of Tako-Tsubo cardiomyopathy (TTC) and acute myocardial infarction (AMI) is similar, both entities are in general only distinguishable by coronary angiography. The purpose of this study was to examine the endogenous stress response at presentation, quantified by the copeptin level, of patients with TTC and patients with AMI, as copeptin may be useful in the non-invasive differentiation between both diseases. METHODS: We compared the endogenous stress response at initial presentation, quantified by the plasma copeptin levels, in 21 consecutive patients finally diagnosed with TTC and 21 patients finally diagnosed with AMI matched for sex and time since chest pain onset. RESULTS: The prevalence of cardiovascular risk factors and initial cardiac troponin T levels were comparable in TTC and AMI. Copeptin levels were significantly lower in patients with TTC when compared to patients with AMI (median 4·8 [interquartile range, IQR 3·5-13·5] pM vs. 25·6 [IQR 12·1-63·9] pM, P = 0·002). The accuracy for diagnosing TTC as quantified by the area under the receiver operating characteristics curve was significantly higher for copeptin than for cardiac troponin T (0·782 vs. 0·549, P = 0·031). The optimal cut-off value for differentiation between TTC and AMI was found at a copeptin level of 7·8 pM (sensitivity 67% at a specificity of 86%, negative predictive value 72%, positive predictive value 82%). CONCLUSIONS: The endogenous stress response, quantified by a novel sensitive biomarker, seems to be different in patients with TTC and AMI. Copeptin levels may be helpful in the non-invasive differentiation between TTC and AMI.
No takes yet. Share an insight, caveat, or question.
Meißner et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: